Rachid Massaad

1.2k total citations
38 papers, 754 citations indexed

About

Rachid Massaad is a scholar working on Surgery, Economics and Econometrics and Computational Theory and Mathematics. According to data from OpenAlex, Rachid Massaad has authored 38 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 16 papers in Economics and Econometrics and 8 papers in Computational Theory and Mathematics. Recurrent topics in Rachid Massaad's work include Lipoproteins and Cardiovascular Health (18 papers), Pharmaceutical Economics and Policy (15 papers) and Computational Drug Discovery Methods (8 papers). Rachid Massaad is often cited by papers focused on Lipoproteins and Cardiovascular Health (18 papers), Pharmaceutical Economics and Policy (15 papers) and Computational Drug Discovery Methods (8 papers). Rachid Massaad collaborates with scholars based in United States, Belgium and Spain. Rachid Massaad's co-authors include Amy O. Johnson‐Levonas, Christopher Allen, Michael J. Davies, Michel Farnier, K. Vandormael, Philippe Brudi, Robert S. Lowe, Christine McCrary Sisk, Chun Sing Lam and Thomas G. Wells and has published in prestigious journals such as Journal of the American College of Cardiology, Kidney International and The American Journal of Cardiology.

In The Last Decade

Rachid Massaad

37 papers receiving 717 citations

Peers

Countries citing papers authored by Rachid Massaad

Since Specialization

Citations

This map shows the geographic impact of Rachid Massaad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachid Massaad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachid Massaad more than expected).

Fields of papers citing papers by Rachid Massaad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachid Massaad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachid Massaad. The network helps show where Rachid Massaad may publish in the future.

Co-authorship network of co-authors of Rachid Massaad

This figure shows the co-authorship network connecting the top 25 collaborators of Rachid Massaad. A scholar is included among the top collaborators of Rachid Massaad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachid Massaad. Rachid Massaad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden 2024 ·Journal of Medical Economics ·(unknown), Kate Young, (unknown), Vimalanand S. Prabhu, Christina Ljungcrantz, Rachid Massaad, Ruifeng Xu, (unknown), (unknown), Robert Orlowski, Linda Duska	0
2	Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice 2023 ·European Journal of Cancer ·Domenica Lorusso, Nicoletta Colombo, Antonio Casado, Alessandro D. Santin, Émeline Colomba, David S. Miller, Keiichi Fujiwara, Sandro Pignata, Sally Baron‐Hay, Isabelle Laure Ray-Coquard, Ronnie Shapira‐Frommer, Yong Man Kim, Mary McCormack, Rachid Massaad, Allison Martin Nguyen, Qi Zhao, Jodi A. McKenzie, Vimalanand S. Prabhu, Vicky Makker	6
3	What is the Preferred Screening Tool for COVID‐19 in Asymptomatic Patients Undergoing a Surgical or Diagnostic Procedure? 2020 ·World Journal of Surgery ·(unknown), Michaël P. A. Bus, Rachid Massaad, (unknown), (unknown), Nathalie M. Delfos, M. van der Feltz, Karen A. Heemstra, (unknown)	18
4	Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia 2015 ·The Journal of Pediatrics ·D. Meeike Kusters, Maria Caceres, (unknown), (unknown), Claude Gagné, Mark Z. Jacobson, Peter O. Kwiterovich, Raymond Lee, Robert S. Lowe, Rachid Massaad, Brian W. McCrindle, (unknown), Joseph Triscari, John J.P. Kastelein	46
5	A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children 2014 ·Clinical Journal of the American Society of Nephrology ·Nicholas J.A. Webb, Thomas G. Wells, Shahnaz Shahinfar, Rachid Massaad, Wayne M. Dankner, Chun Sing Lam, Emanuela Santoro, Christine McCrary Sisk, Robert O. Blaustein	16
6	Losartan and enalapril are comparable in reducing proteinuria in children 2012 ·Kidney International ·Nicholas J.A. Webb, Shahnaz Shahinfar, Thomas G. Wells, Rachid Massaad, Gilbert W. Gleim, Emanuela Santoro, (unknown), Chun Sing Lam	27
7	Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study 2012 ·Lipids in Health and Disease ·(unknown), Fernando Civeira, (unknown), Mary E. Hanson, Rachid Massaad, Celine Le Bailly De Tilleghem, (unknown), Joseph Triscari	12
8	Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome 2012 ·Pediatric Nephrology ·Nicholas J.A. Webb, Shahnaz Shahinfar, Thomas G. Wells, Rachid Massaad, Gilbert W. Gleim, Christine McCrary Sisk, Chun Sing Lam	29
9	Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast 2011 ·Allergy and Asthma Proceedings ·Yasmine Wasfi, James P. Kemp, César Villarán, Rachid Massaad, (unknown), Steven S. Smugar, Barbara Knorr, George Philip	10
10	Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study) 2011 ·The American Journal of Cardiology ·Harold Bays, Michael H. Davidson, Rachid Massaad, (unknown), Robert S. Lowe, Andrew M. Tershakovec, Charlotte Jones-Burton	58
11	A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma 2010 ·Annals of Allergy Asthma & Immunology ·Claudia R. Morris, Allan B. Becker, (unknown), Rachid Massaad, Stuart A. Green, Steven S. Smugar, Deborah M. Gurner	20
12	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study 2009 ·International Journal of Clinical Practice ·Michel Farnier, Maurizio Averna, Luc Missault, H Vaverková, Margus Viigimaa, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas, Philippe Brudi	51
13	Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event 2008 ·Cardiology ·Philippe Brudi, John Reckless, (unknown), (unknown), Sanghyun Lim, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas	4
14	Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study 2008 ·International Journal of Clinical Practice ·John Reckless, Peter J. Henry, (unknown), Sanghyun Lim, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas, Kinga Lis, Philippe Brudi, Christopher Allen	28
15	Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus* 2007 ·Diabetes Obesity and Metabolism ·Christian Constance, Sabine Westphal, N. Chung, (unknown), Christine McCrary Sisk, Amy O. Johnson‐Levonas, Rachid Massaad, Christopher Allen	36
16	LDL-C goal attainment with the addition of ezetimibe to on-going simvastatin treatment in coronary heart disease patients with hypercholesterolemia 2005 ·Current Medical Research and Opinion ·(unknown), Shmuel Banai, A. Marco Alings, Rachid Massaad, Michael J. Davies, Christopher Allen	40
17	Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease 2005 ·International Journal of Clinical Practice ·Vivencio Barrios, Nicolas Amabile, Franck Paganelli, (unknown), Christopher Allen, Amy O. Johnson‐Levonas, Rachid Massaad, K. Vandormael	41
18	Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease 2005 ·International Journal of Cardiology ·Michel Farnier, Massimo Volpe, Rachid Massaad, Michael J. Davies, Christopher Allen	44
19	Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease 2005 ·International Journal of Clinical Practice ·(unknown), Gabriella Bedarida, (unknown), (unknown), Amy O. Johnson‐Levonas, Rachid Massaad	42
20	Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure 2004 ·Annals of Allergy Asthma & Immunology ·Tamara T. Perry, Jonathan Corren, George Philip, Eui Hyeok Kim, Mary Kay Conover-Walker, (unknown), Rachid Massaad, Sairia Dass, Theodore F. Reiss, Robert A. Wood	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact